PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy - Concepedia

Concepedia

Publication | Open Access

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

DOI Full Paper Access

88

Citations

32

References

2020

Year

Wenfeng Fang, Yihua Huang, Weiguang Gu, Jiadi Gan, Wenjing Wang, Shiyue Zhang, K. Wang, Jianhua Zhan, Yunpeng Yang, Yan Huang,

Translational Lung Cancer Research

Abstract

Our study revealed that PI3K pathway was activated in at least 14.9% in EGFR-TKI resistant patients. EGFR-TKIs plus everolimus showed limited antitumor activity in EGFR mutant NSCLC patients with PI3K pathway aberrations.

References

	Year	Citations

Page 1